{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:11:15Z","timestamp":1794006675919,"version":"4.8.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"General Hospital of Northern Theater Command","award":["ZZKY2024018"],"award-info":[{"award-number":["ZZKY2024018"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 82270659"],"award-info":[{"award-number":["Grant No. 82270659"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03291-8","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T16:55:30Z","timestamp":1752771330000},"page":"4210-4223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Interferon in Liver Diseases: Recent Advances"],"prefix":"10.1007","volume":"42","author":[{"given":"Yuting","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6739","authenticated-orcid":false,"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"3291_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coviro.2016.01.001","volume":"16","author":"JR Teijaro","year":"2016","unstructured":"Teijaro JR. Type I interferons in viral control and immune regulation. Curr Opin Virol. 2016;16:31\u201340.","journal-title":"Curr Opin Virol"},{"issue":"5","key":"3291_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jhep.2024.06.016","volume":"81","author":"V Taru","year":"2024","unstructured":"Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024;81(5):895\u2013910.","journal-title":"J Hepatol"},{"key":"3291_CR3","doi-asserted-by":"publisher","first-page":"1437046","DOI":"10.3389\/fimmu.2024.1437046","volume":"15","author":"MN Abdelnabi","year":"2024","unstructured":"Abdelnabi MN, Hassan GS, Shoukry NH. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease. Front Immunol. 2024;15:1437046.","journal-title":"Front Immunol"},{"issue":"1","key":"3291_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","volume":"77","author":"D Huang","year":"2022","unstructured":"Huang D, Wu D, Wang P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42\u201354.","journal-title":"J Hepatol"},{"key":"3291_CR5","doi-asserted-by":"publisher","first-page":"1474342","DOI":"10.3389\/fphar.2024.1474342","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yang X, Tan L, et al. The efficacy and safety of addition of pegylated interferon to long-term nucleos(t)ide analogue therapy on functional cure of chronic hepatitis B patient: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1474342.","journal-title":"Front Pharmacol"},{"key":"3291_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2147\/JHC.S279657","volume":"7","author":"X Gao","year":"2020","unstructured":"Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA initiation after curative treatment and its relationship with the recurrence of HCV-related HCC. J Hepatocell Carcinoma. 2020;7:347\u201360.","journal-title":"J Hepatocell Carcinoma"},{"key":"3291_CR7","doi-asserted-by":"crossref","unstructured":"Muhammad I, Contes K, Bility MT, Tang Q. Chasing virus replication and infection: PAMP-PRR interaction drives type I interferon production, which in turn activates ISG expression and ISGylation. Viruses. 2025;17(4).","DOI":"10.3390\/v17040528"},{"key":"3291_CR8","doi-asserted-by":"crossref","unstructured":"Shi LZ, Bonner JA. Bridging radiotherapy to immunotherapy: the IFN-JAK-STAT axis. Int J Mol Sci. 2021;22(22).","DOI":"10.3390\/ijms222212295"},{"issue":"2","key":"3291_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00018-023-04689-9","volume":"80","author":"KM Hargadon","year":"2023","unstructured":"Hargadon KM. Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. Cell Mol Life Sci. 2023;80(2):40.","journal-title":"Cell Mol Life Sci"},{"issue":"5890","key":"3291_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/300379a0","volume":"300","author":"WF DeGrado","year":"1982","unstructured":"DeGrado WF, Wasserman ZR, Chowdhry V. Sequence and structural homologies among type I and type II interferons. Nature. 1982;300(5890):379\u201381.","journal-title":"Nature"},{"issue":"1","key":"3291_CR11","first-page":"3","volume":"21","author":"S Li","year":"2023","unstructured":"Li S, Fan G, Li X, Cai Y, Liu R. Modulation of type I interferon signaling by natural products in the treatment of immune-related diseases. Chin J Nat Med. 2023;21(1):3\u201318.","journal-title":"Chin J Nat Med"},{"key":"3291_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8\u201332.","journal-title":"Immunol Rev"},{"issue":"5006","key":"3291_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1126\/science.1902591","volume":"252","author":"SE Ealick","year":"1991","unstructured":"Ealick SE, Cook WJ, Vijay-Kumar S, et al. Three-dimensional structure of recombinant human interferon-gamma. Science. 1991;252(5006):698\u2013702.","journal-title":"Science"},{"issue":"6","key":"3291_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","volume":"17","author":"RR Goel","year":"2021","unstructured":"Goel RR, Kotenko SV, Kaplan MJ. Interferon lambda in inflammation and autoimmune rheumatic diseases. Nat Rev Rheumatol. 2021;17(6):349\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"3291_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606489","volume":"11","author":"MR Walter","year":"2020","unstructured":"Walter MR. The role of structure in the biology of interferon signaling. Front Immunol. 2020;11: 606489.","journal-title":"Front Immunol"},{"issue":"44","key":"3291_CR16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409684121","volume":"121","author":"X Xiao","year":"2024","unstructured":"Xiao X, Wang J, Ma J, et al. Interferon lambda 4 is a gut antimicrobial protein. Proc Natl Acad Sci USA. 2024;121(44): e2409684121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3291_CR17","doi-asserted-by":"crossref","unstructured":"Casanova JL, MacMicking JD, Nathan CF. Interferon-\u03b3 and infectious diseases: Lessons and prospects. Science. 2024;384(6693): eadl2016.","DOI":"10.1126\/science.adl2016"},{"issue":"4","key":"3291_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.immuni.2024.03.014","volume":"57","author":"SL Carroll","year":"2024","unstructured":"Carroll SL, Pasare C, Barton GM. Control of adaptive immunity by pattern recognition receptors. Immunity. 2024;57(4):632\u201348.","journal-title":"Immunity"},{"key":"3291_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.812774","volume":"13","author":"T Duan","year":"2022","unstructured":"Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-Like receptor signaling and its role in cell-mediated immunity. Front Immunol. 2022;13: 812774.","journal-title":"Front Immunol"},{"issue":"5","key":"3291_CR20","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1111\/j.1365-2672.2008.03896.x","volume":"105","author":"C Xia","year":"2008","unstructured":"Xia C, Lu M, Zhang Z, et al. TLRs antiviral effect on hepatitis B virus in HepG2 cells. J Appl Microbiol. 2008;105(5):1720\u20137.","journal-title":"J Appl Microbiol"},{"issue":"3","key":"3291_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jcmgh.2016.12.004","volume":"3","author":"L Yang","year":"2017","unstructured":"Yang L, Miura K, Zhang B, et al. TRIF Differentially regulates hepatic steatosis and inflammation\/fibrosis in Mice. Cell Mol Gastroenterol Hepatol. 2017;3(3):469\u201383.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"3291_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","volume":"57","author":"T Kawai","year":"2024","unstructured":"Kawai T, Ikegawa M, Ori D, Akira S. Decoding Toll-like receptors: recent insights and perspectives in innate immunity. Immunity. 2024;57(4):649\u201373.","journal-title":"Immunity"},{"key":"3291_CR23","doi-asserted-by":"crossref","unstructured":"Wicherska-Paw\u0142owska K, Wr\u00f3bel T, Rybka J. Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases. Int J Mol Sci. 2021;22(24).","DOI":"10.3390\/ijms222413397"},{"issue":"1","key":"3291_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-023-01405-9","volume":"16","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Zhang H, Wang J, et al. Exploiting RIG-I-like receptor pathway for cancer immunotherapy. J Hematol Oncol. 2023;16(1):8.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3291_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2024.03.003","volume":"57","author":"M Yoneyama","year":"2024","unstructured":"Yoneyama M, Kato H, Fujita T. Physiological functions of RIG-I-like receptors. Immunity. 2024;57(4):731\u201351.","journal-title":"Immunity"},{"issue":"3","key":"3291_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41423-020-00602-7","volume":"18","author":"K Onomoto","year":"2021","unstructured":"Onomoto K, Onoguchi K, Yoneyama M. Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. Cell Mol Immunol. 2021;18(3):539\u201355.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3291_CR27","doi-asserted-by":"publisher","first-page":"101969","DOI":"10.1016\/j.isci.2020.101969","volume":"24","author":"S Lee","year":"2021","unstructured":"Lee S, Goyal A, Perelson AS, et al. Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes. iScience. 2021;24(1):101969.","journal-title":"iScience"},{"issue":"1","key":"3291_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/liv.15465","volume":"43","author":"MF Yuen","year":"2023","unstructured":"Yuen MF, Chen CY, Liu CJ, et al. A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-na\u00efve patients with chronic hepatitis B. Liver Int. 2023;43(1):77\u201389.","journal-title":"Liver Int"},{"key":"3291_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2024.110199","volume":"599","author":"A Kar","year":"2024","unstructured":"Kar A, Mukherjee S, Mukherjee S, Biswas A. Ubiquitin: A double-edged sword in hepatitis B virus-induced hepatocellular carcinoma. Virology. 2024;599: 110199.","journal-title":"Virology"},{"key":"3291_CR30","doi-asserted-by":"crossref","unstructured":"Qin, Y., B. Xue, C. Liu, et al., NLRX1 mediates MAVS degradation to attenuate the hepatitis C virus-induced innate immune response through PCBP2. J Virol. 2017;91(23).","DOI":"10.1128\/JVI.01264-17"},{"key":"3291_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ijbiomac.2021.10.014","volume":"192","author":"F Kong","year":"2021","unstructured":"Kong F, You H, Zheng K, Tang R, Zheng C. The crosstalk between pattern-recognition receptor signaling and calcium signaling. Int J Biol Macromol. 2021;192:745\u201356.","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"3291_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21(9):548\u201369.","journal-title":"Nat Rev Immunol"},{"key":"3291_CR33","doi-asserted-by":"crossref","unstructured":"Yum S, Li M, Fang Y, Chen ZJ. TBK1 recruitment to STING activates both IRF3 and NF-\u03baB that mediate immune defense against tumors and viral infections. Proc Natl Acad Sci USA. 2021;118(14).","DOI":"10.1073\/pnas.2100225118"},{"issue":"5","key":"3291_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100324","volume":"3","author":"R Chen","year":"2021","unstructured":"Chen R, Du J, Zhu H, Ling Q. The role of cGAS-STING signalling in liver diseases. JHEP Rep. 2021;3(5): 100324.","journal-title":"JHEP Rep"},{"issue":"5","key":"3291_CR35","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215(5):1287\u201399.","journal-title":"J Exp Med"},{"key":"3291_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.metabol.2017.09.010","volume":"81","author":"JT Qiao","year":"2018","unstructured":"Qiao JT, Cui C, Qing L, et al. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metabolism. 2018;81:13\u201324.","journal-title":"Metabolism"},{"issue":"10381","key":"3291_CR37","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401(10381):1039\u201352.","journal-title":"Lancet"},{"issue":"4","key":"3291_CR38","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"5","key":"3291_CR39","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","volume":"79","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, Buti M, Lampertico P, Lee HM. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference. J Hepatol. 2023;79(5):1254\u201369.","journal-title":"J Hepatol"},{"key":"3291_CR40","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/JIR.S477202","volume":"17","author":"Y Yang","year":"2024","unstructured":"Yang Y, Ge F, Luo C, et al. An experimental animal study: electroacupuncture facilitates antiviral immunity against hepatitis B virus through the IFN-\u03b3\/JAK\/STAT axis. J Inflamm Res. 2024;17:6547\u201362.","journal-title":"J Inflamm Res"},{"issue":"4","key":"3291_CR41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/infdis\/jiz143","volume":"220","author":"JH Bockmann","year":"2019","unstructured":"Bockmann JH, Stadler D, Xia Y, et al. Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus-infected hepatocytes. J Infect Dis. 2019;220(4):567\u201377.","journal-title":"J Infect Dis"},{"key":"3291_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608645","volume":"11","author":"ML Stanifer","year":"2020","unstructured":"Stanifer ML, Guo C, Doldan P, Boulant S. Importance of Type I and III interferons at respiratory and intestinal barrier surfaces. Front Immunol. 2020;11: 608645.","journal-title":"Front Immunol"},{"key":"3291_CR43","doi-asserted-by":"publisher","first-page":"1421195","DOI":"10.3389\/fcimb.2024.1421195","volume":"14","author":"J Chen","year":"2024","unstructured":"Chen J, Yin Q, Xu S, et al. IFN-treated macrophage-derived exosomes prevents HBV-HCC migration and invasion via regulating miR-106b-3p\/PCGF3\/PI3K\/AKT signaling axis. Front Cell Infect Microbiol. 2024;14:1421195.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"3291_CR44","doi-asserted-by":"publisher","DOI":"10.4110\/in.2023.23.e30","volume":"23","author":"MLB Hillaire","year":"2023","unstructured":"Hillaire MLB, Lawrence P, Lagrange B. IFN-\u03b3: a crucial player in the fight against HBV infection? Immune Netw. 2023;23(4): e30.","journal-title":"Immune Netw"},{"issue":"4","key":"3291_CR45","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50(4):907\u201323.","journal-title":"Immunity"},{"key":"3291_CR46","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3389\/fimmu.2017.00621","volume":"8","author":"S Phillips","year":"2017","unstructured":"Phillips S, Mistry S, Riva A, et al. Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients. Front Immunol. 2017;8:621.","journal-title":"Front Immunol"},{"issue":"6","key":"3291_CR47","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249\u201362.","journal-title":"J Hepatol"},{"key":"3291_CR48","doi-asserted-by":"publisher","first-page":"1034968","DOI":"10.3389\/fimmu.2022.1034968","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Sun B, Zhuo Y, et al. Interferon and interferon-stimulated genes in HBV treatment. Front Immunol. 2022;13:1034968.","journal-title":"Front Immunol"},{"issue":"3","key":"3291_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jhep.2020.05.032","volume":"73","author":"A Virz\u00ec","year":"2020","unstructured":"Virz\u00ec A, Roca Suarez AA, Lupberger J. Interferon revisited: Peering behind the lines of antiviral defense. J Hepatol. 2020;73(3):496\u20138.","journal-title":"J Hepatol"},{"key":"3291_CR50","doi-asserted-by":"crossref","unstructured":"EASL recommendations on treatment of hepatitis C: final update of the series (\u2606). J Hepatol. 2020;73(5): 1170\u20131218","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"3291_CR51","doi-asserted-by":"crossref","unstructured":"Sung PS, Shin EC. Interferon response in hepatitis C virus-infected hepatocytes: issues to consider in the era of direct-acting antivirals. Int J Mol Sci. 2020;21(7).","DOI":"10.3390\/ijms21072583"},{"key":"3291_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.06.006","volume":"124","author":"F Vahedi","year":"2019","unstructured":"Vahedi F, Lee AJ, Collins SE, et al. IL-15 and IFN-\u03b3 signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. Cytokine. 2019;124: 154439.","journal-title":"Cytokine"},{"key":"3291_CR53","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023;79(2): 433-460","DOI":"10.1016\/j.jhep.2023.05.001"},{"issue":"24","key":"3291_CR54","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1001\/jama.2023.23242","volume":"330","author":"F Negro","year":"2023","unstructured":"Negro F, Lok AS. Hepatitis D: a review. JAMA. 2023;330(24):2376\u201387.","journal-title":"JAMA"},{"key":"3291_CR55","doi-asserted-by":"publisher","first-page":"1287367","DOI":"10.3389\/fimmu.2023.1287367","volume":"14","author":"C Groth","year":"2023","unstructured":"Groth C, Maric J, Garc\u00e9s L\u00e1zaro I, et al. Hepatitis D infection induces IFN-\u03b2-mediated NK cell activation and TRAIL-dependent cytotoxicity. Front Immunol. 2023;14:1287367.","journal-title":"Front Immunol."},{"issue":"7","key":"3291_CR56","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cmi.2020.03.039","volume":"26","author":"GW Webb","year":"2020","unstructured":"Webb GW, Dalton HR. Hepatitis E: an expanding epidemic with a range of complications. Clin Microbiol Infect. 2020;26(7):828\u201332.","journal-title":"Clin Microbiol Infect"},{"key":"3291_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154816","volume":"125","author":"K Murata","year":"2020","unstructured":"Murata K, Kang JH, Nagashima S, et al. IFN-\u03bb3 as a host immune response in acute hepatitis E virus infection. Cytokine. 2020;125: 154816.","journal-title":"Cytokine"},{"issue":"6","key":"3291_CR58","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4254\/wjh.v16.i6.867","volume":"16","author":"J Soldera","year":"2024","unstructured":"Soldera J. Immunological crossroads: the intriguing dance between hepatitis C and autoimmune hepatitis. World J Hepatol. 2024;16(6):867\u201370.","journal-title":"World J Hepatol"},{"issue":"8","key":"3291_CR59","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3748\/wjg.v30.i8.799","volume":"30","author":"E Gigi","year":"2024","unstructured":"Gigi E, Lagopoulos V, Liakos A. Management of autoimmune hepatitis induced by hepatitis delta virus. World J Gastroenterol. 2024;30(8):799\u2013805.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3291_CR60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","volume":"13","author":"EI Rigopoulou","year":"2013","unstructured":"Rigopoulou EI, Zachou K, Gatselis N, Koukoulis GK, Dalekos GN. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. Ann Hepatol. 2013;13(1):127\u201335.","journal-title":"Ann Hepatol"},{"key":"3291_CR61","doi-asserted-by":"crossref","unstructured":"Ghazarian M, Revelo XS, N\u00f8hr MK, et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci Immunol. 2017;2(10).","DOI":"10.1126\/sciimmunol.aai7616"},{"issue":"2","key":"3291_CR62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41423-021-00832-3","volume":"19","author":"A Herrero-Cervera","year":"2022","unstructured":"Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol. 2022;19(2):177\u201391.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"3291_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41573-019-0054-z","volume":"19","author":"T N\u00e9meth","year":"2020","unstructured":"N\u00e9meth T, Sperandio M, M\u00f3csai A. Neutrophils as emerging therapeutic targets. Nat Rev Drug Discov. 2020;19(4):253\u201375.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"3291_CR64","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","volume":"22","author":"T Huby","year":"2022","unstructured":"Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22(7):429\u201343.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3291_CR65","doi-asserted-by":"publisher","first-page":"21085","DOI":"10.1038\/s41598-024-72151-2","volume":"14","author":"Z Fang","year":"2024","unstructured":"Fang Z, Liu C, Yu X, et al. Identification of neutrophil extracellular trap-related biomarkers in non-alcoholic fatty liver disease through machine learning and single-cell analysis. Sci Rep. 2024;14(1):21085.","journal-title":"Sci Rep"},{"issue":"21","key":"3291_CR66","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1182\/blood.2021013565","volume":"139","author":"EGG Sprenkeler","year":"2022","unstructured":"Sprenkeler EGG, Tool ATJ, Henriet SSV, van Bruggen R, Kuijpers TW. Formation of neutrophil extracellular traps requires actin cytoskeleton rearrangements. Blood. 2022;139(21):3166\u201380.","journal-title":"Blood"},{"key":"3291_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.751802","volume":"12","author":"S Hwang","year":"2021","unstructured":"Hwang S, Yun H, Moon S, Cho YE, Gao B. Role of neutrophils in the pathogenesis of nonalcoholic steatohepatitis. Front Endocrinol (Lausanne). 2021;12: 751802.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3291_CR68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41423-020-00579-3","volume":"18","author":"H Wang","year":"2021","unstructured":"Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol. 2021;18(1):73\u201391.","journal-title":"Cell Mol Immunol"},{"key":"3291_CR69","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.3389\/fimmu.2019.02190","volume":"10","author":"E Pylaeva","year":"2019","unstructured":"Pylaeva E, Bordbari S, Spyra I, et al. Detrimental effect of type I IFNs during acute lung infection with pseudomonas aeruginosa is mediated through the stimulation of neutrophil NETosis. Front Immunol. 2019;10:2190.","journal-title":"Front Immunol"},{"issue":"6","key":"3291_CR70","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jhep.2021.07.032","volume":"75","author":"H Wang","year":"2021","unstructured":"Wang H, Zhang H, Wang Y, et al. Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. J Hepatol. 2021;75(6):1271\u201383.","journal-title":"J Hepatol"},{"issue":"8","key":"3291_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101144","volume":"4","author":"Y Pan","year":"2023","unstructured":"Pan Y, Chen H, Zhang X, et al. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. Cell Rep Med. 2023;4(8): 101144.","journal-title":"Cell Rep Med"},{"issue":"1","key":"3291_CR72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.","journal-title":"Signal Transduct Target Ther"},{"key":"3291_CR73","doi-asserted-by":"crossref","unstructured":"Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. J Clin Invest. 2024;134(3).","DOI":"10.1172\/JCI176345"},{"issue":"1\u20132","key":"3291_CR74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2010.05.008","volume":"112","author":"L Ye","year":"2010","unstructured":"Ye L, Wang S, Wang X, et al. Alcohol impairs interferon signaling and enhances full cycle hepatitis C virus JFH-1 infection of human hepatocytes. Drug Alcohol Depend. 2010;112(1\u20132):107\u201316.","journal-title":"Drug Alcohol Depend"},{"key":"3291_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.629141","volume":"11","author":"R Yue","year":"2020","unstructured":"Yue R, Wei X, Zhao J, Zhou Z, Zhong W. Essential role of IFN-\u03b3 in regulating gut antimicrobial peptides and microbiota to protect against alcohol-induced bacterial translocation and hepatic inflammation in mice. Front Physiol. 2020;11: 629141.","journal-title":"Front Physiol"},{"issue":"2","key":"3291_CR76","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/hep.24059","volume":"53","author":"J Petrasek","year":"2011","unstructured":"Petrasek J, Dolganiuc A, Csak T, et al. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology. 2011;53(2):649\u201360.","journal-title":"Hepatology"},{"key":"3291_CR77","doi-asserted-by":"crossref","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4).","DOI":"10.3390\/cells9040875"},{"issue":"1","key":"3291_CR78","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/hep.26981","volume":"60","author":"YS Roh","year":"2014","unstructured":"Roh YS, Park S, Kim JW, et al. Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis. Hepatology. 2014;60(1):237\u201349.","journal-title":"Hepatology"},{"issue":"3","key":"3291_CR79","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajpath.2019.11.012","volume":"190","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Kim JW, Qi J, et al. Toll-like receptor 5 signaling ameliorates liver fibrosis by inducing interferon \u03b2-modulated IL-1 receptor antagonist in mice. Am J Pathol. 2020;190(3):614\u201329.","journal-title":"Am J Pathol"},{"issue":"4","key":"3291_CR80","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1365-2567.2007.02672.x","volume":"122","author":"J Tanabe","year":"2007","unstructured":"Tanabe J, Izawa A, Takemi N, et al. Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects. Immunology. 2007;122(4):562\u201370.","journal-title":"Immunology"},{"issue":"1","key":"3291_CR81","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jhep.2023.02.026","volume":"79","author":"CP Hackstein","year":"2023","unstructured":"Hackstein CP, Spitzer J, Symeonidis K, et al. Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury. J Hepatol. 2023;79(1):150\u201366.","journal-title":"J Hepatol"},{"key":"3291_CR82","doi-asserted-by":"crossref","unstructured":"Liu J, Wang F, Luo F. The role of JAK\/STAT pathway in fibrotic diseases: molecular and cellular mechanisms. Biomolecules. 2023;13(1).","DOI":"10.3390\/biom13010119"},{"issue":"5","key":"3291_CR83","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1053\/j.gastro.2004.08.055","volume":"127","author":"R Sun","year":"2004","unstructured":"Sun R, Gao B. Negative regulation of liver regeneration by innate immunity (natural killer cells\/interferon-gamma). Gastroenterology. 2004;127(5):1525\u201339.","journal-title":"Gastroenterology"},{"key":"3291_CR84","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1038\/ncomms7422","volume":"6","author":"M Eslam","year":"2015","unstructured":"Eslam M, Hashem AM, Leung R, et al. Interferon-\u03bb rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun. 2015;6:6422.","journal-title":"Nat Commun"},{"issue":"5","key":"3291_CR85","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/ng.3836","volume":"49","author":"M Eslam","year":"2017","unstructured":"Eslam M, McLeod D, Kelaeng KS, et al. IFN-\u03bb3, not IFN-\u03bb4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet. 2017;49(5):795\u2013800.","journal-title":"Nat Genet"},{"key":"3291_CR86","doi-asserted-by":"crossref","unstructured":"Maslennikov R, Poluektova E, Zolnikova O, et al. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis. Int J Mol Sci. 2023;24(22).","DOI":"10.3390\/ijms242216502"},{"issue":"3","key":"3291_CR87","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558\u201377.","journal-title":"J Hepatol"},{"issue":"3","key":"3291_CR88","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/hep.30349","volume":"70","author":"L Mu\u00f1oz","year":"2019","unstructured":"Mu\u00f1oz L, Borrero MJ, \u00dabeda M, et al. Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis. Hepatology. 2019;70(3):925\u201338.","journal-title":"Hepatology"},{"issue":"10127","key":"3291_CR89","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314.","journal-title":"Lancet"},{"issue":"10360","key":"3291_CR90","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362.","journal-title":"Lancet"},{"issue":"1","key":"3291_CR91","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12072-023-10618-6","volume":"18","author":"JX Luo","year":"2024","unstructured":"Luo JX, Zhang Y, Hu XY, Xiang N. Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis. Hepatol Int. 2024;18(1):63\u201372.","journal-title":"Hepatol Int"},{"issue":"1","key":"3291_CR92","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jss.2010.07.023","volume":"172","author":"Y Arakawa","year":"2012","unstructured":"Arakawa Y, Shimada M, Utsunomiya T, et al. Effects of pegylated interferon \u03b12b on metastasis of hepatocellular carcinoma. J Surg Res. 2012;172(1):95\u2013101.","journal-title":"J Surg Res"},{"issue":"6","key":"3291_CR93","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1290\/1071-2690(2000)036<0387:UROECA>2.0.CO;2","volume":"36","author":"T Masuda","year":"2000","unstructured":"Masuda T, Saito H, Kaneko F, et al. Up-regulation of E-cadherin and I-catenin in human hepatocellular carcinoma cell lines by sodium butyrate and interferon-alpha. In Vitro Cell Dev Biol Anim. 2000;36(6):387\u201394.","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"5","key":"3291_CR94","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5483\/BMBRep.2023-0024","volume":"56","author":"M Choi","year":"2023","unstructured":"Choi M, Shin J, Lee CE, et al. Immunogenic cell death in cancer immunotherapy. BMB Rep. 2023;56(5):275\u201386.","journal-title":"BMB Rep"},{"issue":"41","key":"3291_CR95","doi-asserted-by":"publisher","first-page":"71249","DOI":"10.18632\/oncotarget.19531","volume":"8","author":"RFV Medrano","year":"2017","unstructured":"Medrano RFV, Hunger A, Mendonca SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 2017;8(41):71249\u201384.","journal-title":"Oncotarget"},{"issue":"16","key":"3291_CR96","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400808RR","volume":"38","author":"D Wang","year":"2024","unstructured":"Wang D, Chen K, Wang Z, Wu H, Li Y. Research progress on interferon and cellular senescence. Faseb J. 2024;38(16): e70000.","journal-title":"Faseb J"},{"key":"3291_CR97","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortega MB, Aparicio E, Gri\u00f1\u00e1n-Lis\u00f3n C, et al. Interferon-alpha decreases cancer stem cell properties and modulates exosomes in malignant melanoma. Cancers (Basel). 2023. 15(14).","DOI":"10.3390\/cancers15143666"},{"issue":"7","key":"3291_CR98","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","volume":"12","author":"B Hu","year":"2022","unstructured":"Hu B, Yu M, Ma X, et al. IFN\u03b1 potentiates Anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov. 2022;12(7):1718\u201341.","journal-title":"Cancer Discov"},{"issue":"6","key":"3291_CR99","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","volume":"19","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Chen M, Xu D, et al. The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma. Cell Mol Immunol. 2022;19(6):726\u201337.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3291_CR100","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","volume":"164","author":"PK Haber","year":"2023","unstructured":"Haber PK, Castet F, Torres-Martin M, et al. Molecular markers of response to Anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology. 2023;164(1):72-88.e18.","journal-title":"Gastroenterology"},{"issue":"9","key":"3291_CR101","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00262-020-02586-9","volume":"69","author":"Y Yan","year":"2020","unstructured":"Yan Y, Zheng L, Du Q, Yan B, Geller DA. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother. 2020;69(9):1891\u2013903.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"3291_CR102","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","volume":"22","author":"X Zhang","year":"2017","unstructured":"Zhang X, Zeng Y, Qu Q, et al. PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 2017;22(6):1026\u201333.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"3291_CR103","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-024-01980-4","volume":"9","author":"L Wang","year":"2024","unstructured":"Wang L, Zhu Y, Zhang N, et al. The multiple roles of interferon regulatory factor family in health and disease. Signal Transduct Target Ther. 2024;9(1):282.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"3291_CR104","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","volume":"82","author":"M Buti","year":"2025","unstructured":"Buti M, Heo J, Tanaka Y, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B. J Hepatol. 2025;82(2):222\u201334.","journal-title":"J Hepatol"},{"issue":"1","key":"3291_CR105","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12985-024-02512-w","volume":"21","author":"Y Li","year":"2024","unstructured":"Li Y, Yang S, Li C, et al. Efficacy of short-term Peg-IFN \u03b1-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study. Virol J. 2024;21(1):231.","journal-title":"Virol J"},{"issue":"10","key":"3291_CR106","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1136\/gutjnl-2024-332290","volume":"73","author":"A Vecchi","year":"2024","unstructured":"Vecchi A, Rossi M, Tiezzi C, et al. HBcrAg values may predict virological and immunological responses to pegIFN-\u03b1 in NUC-suppressed HBeAg-negative chronic hepatitis B. Gut. 2024;73(10):1737\u201348.","journal-title":"Gut"},{"issue":"4","key":"3291_CR107","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1002\/imt2.143","volume":"2","author":"H Xia","year":"2023","unstructured":"Xia H, Zhang Z, Luo C, et al. MultiPrime: A reliable and efficient tool for targeted next-generation sequencing. iMeta. 2023;2(4):e143.","journal-title":"iMeta"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03291-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03291-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03291-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:25:21Z","timestamp":1757258721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03291-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3291"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03291-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}